



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Product Information

<b>Description:</b>	Recombinant human cadherin17 (CDH17), encompassing amino acids 23-787. This construct contains a C-terminal Avi-Tag™ followed by an His-tag (6xHis). This protein was affinity purified.
<b>Background:</b>	CHD17 (cadherin 17), also known as LI (liver-intestine)-cadherin is a unique member of the cadherin superfamily of proteins, as it has seven instead of the five typical cadherin domains. It is a calcium-dependent membrane-associated glycoprotein normally expressed on epithelial cells of the small intestine and colon, where it regulates intercellular adhesion. Upregulation of this protein is found in gastric cancer, colorectal and pancreatic cancer, amongst others. CHD17 has become a therapeutic target of interest, with studies using monoclonal antibodies, ADC (antibody drug conjugates) and CAR-T cells resulting in promising outcomes. More recently nanobodies, with their smaller size and higher potential to penetrate tumors, have also been developed. A bispecific T cell engager, ARB202, has shown great promise <i>in vitro</i> . CHD17 is thus a target with great potential and future studies will continue to open new avenues of treatment around it.
<b>Species</b>	Human
<b>Construct:</b>	Cadherin17 (23-787-Avi-His)
<b>Concentration:</b>	1.71 mg/ml
<b>Expression System:</b>	HEK293
<b>Purity:</b>	≥90%
<b>Format:</b>	Aqueous buffer solution.
<b>Formulated In:</b>	40 mM Tris-HCl pH 8.0, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
<b>MW:</b>	88.2 kDa + glycans
<b>Glycosylation:</b>	This protein runs at a higher MW by SDS-PAGE due to glycosylation
<b>Genbank Accession:</b>	NM_004063.4
<b>Stability:</b>	At least 6 months at -80°C.
<b>Storage:</b>	-80°C
<b>Instructions for Use:</b>	Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
<b>Assay Conditions:</b>	This protein was tested using an Alpha-LISA™ binding assay. A 10 µl reaction mix containing E-cadherin in 1x PP-02 Buffer was incubated with Cadherin17, Fc-fusion (IgG1), Avi-Tag, Biotin-Labeled Recombinant for one hour at room temperature. Protein A acceptor beads were added, and the reaction was incubated for 30 minutes, followed by the addition of Nickel Donor beads. A-counts were measured. The net A-count signal is proportional to E-cadherin-Cadherin17 binding.
<b>Applications:</b>	Useful for binding assays.

Quality Control Data

4-20% SDS-PAGE Coomassie Staining



Cadherin17 binding to E-cadherin

